Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8  T Cell Effector Function

Buchan et  al. reveal dual anti-tumor activities for antibodies to the co-stimulatory receptor 4-1BB, which depend on antibody isotype and FcγR availability. Sequential scheduling of anti-4-1BB and checkpoint blockade mAbs, and antibodies engineered to harness both Treg cell depleting and effector cell agon ism properties show potent anti-tumor activity in preclinical models, laying the groundwork for translation into the clinic.

Source: Immunity - November 13, 2018 Category: Allergy & Immunology Authors: Sarah L. Buchan, Lang Dou, Marcus Remer, Steven G. Booth, Stuart N. Dunn, Chester Lai, Monika Semmrich, Ingrid Teige, Linda M årtensson, Christine A. Penfold, H.T. Claude Chan, Jane E. Willoughby, C. Ian Mockridge, Lekh N. Dahal, Kirstie L.S. Cleary, Son Tags: Article Source Type: research